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OBJECTIVE: A large Veterans Integrated Service Network
(VISN16) mandated in October 2003 metabolic monitoring prior
to initiation of any antipsychotic. This study focused on schizo-
phrenia patients who were initiated at VISN 16 on any atypical
antipsychotic, and compared patient characteristics and resource
utilization of patients who have undergone metabolic monitoring
versus those who have not. METHODS: We used VISN16 elec-
tronic medical records data for October 2002–August 2005 to
identify schizophrenia patients who were initiated on any atypical
antipsychotic. Patients who have undergone metabolic monitor-
ing in the 180 days prior tomedication initiation (MetMon+) were
compared to patients who did not (MetMon-), on patient char-
acteristics and resource utilization in the 1-year prior to medica-
tion initiation. Logistic regression was used to identify predictors
of undergoing metabolic monitoring. RESULTS: Most patients
(3568 of 4709, or 75.8%) have undergone metabolic monitoring.
Compared to the MetMon- group, the MetMon+ patients were
more likely to be overweight or obese (40.8% vs. 19.4%,
p < 0.001), were more likely to be hospitalized in the prior year
(49.6% vs. 31.5%, p < 0.001), had a higher Charlson Comorbid-
ity Index score (0.67 versus 0.46 p < 0.001), a higher rate of
substance use disorders (45.3% vs. 35.8% p < 0.001), more ofﬁce
visits (23.5 vs. 15.9, p < 0.001), a longer duration of antipsychotic
use (208.7 days vs. 160.0 days p < 0.001), a higher medication
possession ratio (59% vs. 47%p < 0.001), and a larger number of
different antipsychotic drugs (1.6 vs. 1.5, p < 0.001). The logistic
regression model conﬁrmed differences in patient characteristics
and utilization patterns. CONCLUSION: A majority of the VISN
16 schizophrenia patients have undergone metabolic monitoring
prior to initiation of atypical antipsychotics. Compared to
patients who did not undergo metabolic monitoring, those who
did were more likely to be overweight or obese and manifest a
more severe illness proﬁle.
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OBJECTIVE: Although a few of case reports and two case-
controls studies were available, the data regarding the risk of
neuroleptic malignant syndrome (NMS) associated with the use
of antipsychotic, particularly the potency of Dopamine 2 (D2)
inhibitions, and other risk factors is limited. It aims to examine
the risk of NMS associated with the use of antipsychotic, in
particular potency of D2 inhibition, and other risk factors.
METHODS: A retrospective, population-based case-control
study is performed using a managed care medical claims data-
base. Among 154,474 patients with bipolar disorder, a total of
50 cases with NMS during the study period are identiﬁed and
matched with 800 controls by age, and the year of the index date
of bipolar disorder. Antipsychotics are grouped based upon the
potency of D2 receptor that is measured by Ki values. Persons
with ever other antipsychoitcs (except the high-potency antipsy-
chotics) prescribed are then deﬁned as low-potency antipsychotic
users (Ki  1 nM). RESULTS: The use of antipsychotic is asso-
ciated with a 2.36-fold increased risk of NMS after controlling
the other risk factors (95% conﬁdence interval [CI] = 1.08 to
5.19). Besides the use of antipsychotic, being male is associated
with a 2-fold increased risk of NMS. Other risk factors, including
the previous history of delirium, confusion, dehydration, and
extrapyramdial signs, can signiﬁcantly increase the risk of
NMS . The adjusted ORs for the patients with the use of low-
potency antipsychotics and high-potency antipsychotics are 1.47
(95%CI = 0.49 to 4.42), and 3.91 (95%CI = 1.38 to 11.14),
respectively, as compared to non-users. CONCLUSION: Besides
the use of antipsychotic, other factors including being male,
presence of delirium, confusion, dehydration, and extrapyram-
dial signs could signiﬁcantly increase the risk of NMS. The
magnitude of the risk of NMS seems to be related to an anti-
psychotic potency of D2 inhibition.
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OBJECTIVE: To evaluate the clinical effectiveness and economic
implications of the ﬁrst year of treatment with atypical antipsy-
chotics (AAPs) (risperidone, olanzapine, quetiapine, and clozap-
ine) in patients with schizophrenia, to the Canadian publicly
funded drug plans. METHODS: We synthesized the ﬁndings
from a recent drug class review on AAPs and conducted a review
of pharmacoeconomic studies. A decision tree model estimated
the costs of the ﬁrst year of treatment, accounting for the likeli-
hood of switching from one AAP to another as patients progress
from ﬁrst to second line (risperidone, olanzapine and quetiapine)
and third-line therapy options (clozapine). RESULTS: We could
identify no high-quality evidence that could directly inform
public policy questions regarding which atypical antipsychotics
represent optimal treatment decisions for ﬁrst-line therapy. The
results of this study were based largely on two trials and one
observational study, with patient populations of potentially
limited generalizability. The ﬁrst-year prescription costs for each
new patient with risperidone, quetiapine, olanzapine, and cloza-
pine are $1703, $3454, $4285, and $6989, respectively (using
the publicly drug plan costs in 2005). Accounting for the total
treatment costs to the ministries of health (e.g., prescription,
hospitalization, outpatients, group home, laboratory, and DM
and EPS), the ﬁrst year cost of treatment starting with risperi-
done, olanzapine, quetiapine and clozapine respectively are:
$17,950, $18,327, $19,695, and $44,172 (all in 2005 Canadian
dollars). Depending on dose used and drug costs and accounting
for signiﬁcant clinical events (e.g. relapse), total treatment costs
to the ministries of health range from $16,188 to $19,167 start-
ing with risperidone, $16,096 to $19,718 with olanzapine, and
$18,050 to $20,556 with quetiapine. CONCLUSION: Olanza-
pine and risperidone are clinically more effective over quetiapine
when used as ﬁrst- or second-line therapy options for schizophre-
nia. Their lower relapse and discontinuation rates resulted to
more attractive economic implications to payers from the public
sector.
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